ArticleFrontiers in cellular and infection microbiology2025
Shaoyao Gancao decoction alleviates functional constipation by inhibiting
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Shaoyao Gancao Decoction (SGD), a classical traditional Chinese medicine formula, has been clinically reported to improve symptoms of functional constipation (FC), although its underlying mechanisms remain unclear. This study aimed to explore the clinical efficacy and gut microbiota modulation of SGD in patients with FC. Methods: A self-controlled pilot study was conducted in 20 patients diagnosed with FC according to the Rome III (IV) criteria. Participants received a 3-5 day oral intervention with SGD. Clinical outcomes, including stool frequency, consistency, and ease of defecation, were evaluated using self-reported questionnaires. Fecal samples collected before and after treatment were analyzed for microbial composition (16S rRNA sequencing) and short-chain fatty acids (SCFAs). Results: Ninety percent of participants reported symptomatic improvement, with 70% achieving increased stool frequency (> 3 times/week). SGD treatment markedly shifted the fecal microbiota from a dysbiotic state dominated by Discussion: These findings suggest that SGD alleviates FC by restoring microbial balance, enhancing SCFA production, and suppressing dysbiosis-induced endocannabinoid signaling. As a pilot study, the results are preliminary but provide mechanistic insights that warrant validation in larger, randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.